How Long Can You Live with Prostate Cancer?

How long a person can live with prostate cancer varies widely, but many people diagnosed with localized disease live for many years or decades and may be cured. Even when prostate cancer has spread, modern treatments can often control it for a long time while supporting quality of life.

How long can you live with prostate cancer?

How long a person can live with prostate cancer depends on the cancer’s stage, grade, prostate-specific antigen (PSA) level, location, overall health and response to treatment. Many people with cancer that is confined to the prostate live for decades, and treatment may be curative. Some prostate cancers grow so slowly that careful monitoring is appropriate for a period of time.

When prostate cancer has spread beyond the prostate, it is generally more difficult to cure. However, it can often be controlled for years with hormone therapy, targeted medicines, chemotherapy, radiation and other treatments selected for the individual. Prognosis statistics describe large groups of people, not one person’s future, so a cancer specialist is best placed to interpret them in the context of pathology and imaging results.

It can be helpful to ask the care team whether the cancer is localized, regional or metastatic, whether it is low-, intermediate- or high-risk, and what the goal of treatment is. These details provide more meaningful information than a diagnosis alone.

What shapes prostate cancer outlook?

Doctors assess prostate cancer using several connected factors. The stage describes how far cancer has grown or spread. Localized cancer remains within the prostate, regional cancer has extended to nearby tissues or lymph nodes, and metastatic cancer has spread to distant parts of the body, commonly bones or lymph nodes.

The Gleason score, now often reported as a Grade Group, describes how abnormal cancer cells appear under a microscope. Higher-grade cancers are more likely to grow and spread. PSA blood-test results, findings on MRI or other scans, the number of biopsy samples containing cancer and changes over time also help guide prognosis and treatment planning.

Age and general health matter when considering treatment choices, but they do not determine outlook by themselves. A person’s preferences, possible treatment side effects and other medical conditions should be included in shared decision-making. More background on the diagnosis is available in prostate cancer information.

• Localized, lower-risk disease often has a very favorable outlook.
• Higher-risk localized disease may need combination treatment to reduce recurrence risk.
• Recurrent or metastatic disease needs ongoing monitoring and individualized systemic treatment.

What is the 10-year survival rate for stage 2 prostate cancer?

Stage 2 prostate cancer is generally confined to the prostate but may be larger, involve more of the gland or have features suggesting a higher risk than stage 1 disease. In population-based reporting, localized prostate cancer has a very high relative survival rate, with many sources reporting that more than 99% of people are alive five years after diagnosis. Ten-year outcomes for stage 2 disease are also generally excellent, especially when the cancer is appropriately monitored or treated.

A single 10-year survival percentage for stage 2 cancer can be misleading because stage 2 includes cancers with different PSA levels, Grade Groups and volumes of disease. Relative survival also compares people with prostate cancer with people in the general population; it does not predict whether a particular person will die from prostate cancer.

For an individual estimate, the urologist or oncologist may use clinical stage, MRI findings, PSA, biopsy results and general health. They can also explain the difference between overall survival, cancer-specific survival and the chance that treatment will keep the cancer under control.

Can prostate cancer be cured if it has spread?

Prostate cancer that has spread to distant organs or bones is usually not considered curable with currently available standard treatments. Nevertheless, it is often treatable, and many people live for years with metastatic prostate cancer. The purpose of treatment is to slow cancer growth, delay complications, reduce symptoms and preserve day-to-day wellbeing.

In selected situations, such as a small number of metastatic sites, doctors may use a combination of systemic treatment and focused radiation. Research continues to improve treatment options. Some people have long-lasting responses, but the medical team will usually speak about disease control rather than cure when cancer is metastatic.

If cancer has spread only to nearby areas or lymph nodes, curative-intent treatment may still be possible in some cases. Treatment can include radiation to the prostate and surrounding area with hormone therapy, or surgery followed by additional treatment when needed. The exact meaning of “spread” should therefore be clarified with the treating specialist.

What stage of prostate cancer requires hormone treatment?

Hormone treatment, also called androgen-deprivation therapy (ADT), is not required for every stage of prostate cancer. It is most commonly used when cancer has spread beyond the prostate, has returned after previous treatment, or is high-risk and needs to be treated alongside radiation therapy. Prostate cancer cells commonly use male hormones, particularly testosterone, to grow; ADT lowers or blocks the effect of these hormones.

For localized low-risk cancer, hormone therapy is usually not used alone because active surveillance, surgery or radiation may be more appropriate depending on the circumstances. For unfavorable intermediate-risk or high-risk localized cancer, a limited course of ADT may be recommended with radiation. For metastatic disease, ADT is typically a core part of treatment and may be combined with newer hormone-blocking medicines, chemotherapy or other therapies.

Hormone therapy can cause side effects such as hot flushes, fatigue, reduced sexual desire, erection changes, loss of muscle mass, weight changes and bone thinning. The care team can discuss ways to monitor and manage these effects, including exercise, nutrition, bone health assessments and supportive medicines when appropriate. Hormone therapy for cancer should always be planned and monitored by an experienced oncology team.

Modern treatment and monitoring options

Treatment is tailored to the cancer’s risk level and the person’s needs. Active surveillance involves regular PSA testing, examinations, imaging and sometimes repeat biopsy. It is commonly used for selected low-risk cancers and can help avoid or delay treatment side effects without ignoring the cancer.

For cancer confined to the prostate, options may include surgery to remove the prostate, external-beam radiation therapy or brachytherapy in appropriate cases. Higher-risk disease may be treated with a combination of radiation and hormone therapy. Treatment decisions should take account of possible urinary, bowel and sexual side effects, as well as the likelihood of cancer control.

For advanced disease, doctors may recommend ADT with additional hormone-targeting medicines, chemotherapy, radiation for painful or high-risk bone areas, radiopharmaceutical treatments, immunotherapy or targeted treatment when suitable. Genetic and tumor testing may identify people who could benefit from particular medicines. Radiotherapy can be used with curative intent in localized disease and to help control symptoms in advanced disease.

Regular follow-up is important after any approach. PSA trends, symptoms, imaging and treatment tolerability help the team decide whether the plan should continue or change.

What are the common symptoms of prostate cancer at the end of life?

Not everyone with advanced prostate cancer experiences the same symptoms, and good palliative care can prevent or ease many problems. Near the end of life, a person may become increasingly tired, sleep more, eat and drink less, lose weight or become less able to carry out usual activities. These changes can also occur for reasons unrelated to cancer and should be discussed with the clinical team.

If cancer affects the bones, some people experience pain, weakness or reduced mobility. Other possible concerns include nausea, constipation, breathlessness, anxiety, confusion or difficulty passing urine, depending on the cancer’s location and other health conditions. Severe or new back pain, leg weakness, numbness around the groin, or new loss of bladder or bowel control requires urgent medical assessment because it may indicate spinal cord compression.

Palliative care is specialized support for symptoms, emotional wellbeing and practical needs. It can be provided alongside cancer treatment, not only in the final days of life. Families and caregivers can also receive guidance on comfort, communication and available support services.

When to seek medical care

A person should arrange a medical review for persistent urinary changes, blood in urine or semen, unexplained bone pain, unintentional weight loss or new erectile difficulties that are causing concern. These symptoms are often caused by non-cancerous conditions, such as an enlarged prostate or infection, but evaluation can identify the cause and guide care.

Urgent assessment is needed for inability to pass urine, severe and worsening back pain, new leg weakness or numbness, loss of bladder or bowel control, or severe uncontrolled pain. People already receiving treatment should contact their cancer team promptly about new or rapidly worsening symptoms, treatment side effects or emotional distress.

Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals support international patients with prostate cancer diagnosis, treatment planning and follow-up care. A urologist, radiation oncologist and medical oncologist can help explain the likely outlook and treatment choices for an individual situation.

Frequently asked questions